WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H596765
CAS#: 170902-47-3
Description: Roxifiban is a prodrug whose methyl-ester is hydrolysed following oral adminstration to form the GPIIb/GPIIIA antagonist XV459.
Hodoodo Cat#: H596765
Name: Roxifiban
CAS#: 170902-47-3
Chemical Formula: C21H29N5O6
Exact Mass: 447.21
Molecular Weight: 447.490
Elemental Analysis: C, 56.37; H, 6.53; N, 15.65; O, 21.45
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: Roxifiban; DMP754; DMP 754; DMP-754;
IUPAC/Chemical Name: methyl (S)-2-((butoxycarbonyl)amino)-3-(2-((R)-3-(4-carbamimidoylphenyl)-4,5-dihydroisoxazol-5-yl)acetamido)propanoate
InChi Key: IRAXRQFCCSHQDX-WBVHZDCISA-N
InChi Code: InChI=1S/C21H29N5O6/c1-3-4-9-31-21(29)25-17(20(28)30-2)12-24-18(27)11-15-10-16(26-32-15)13-5-7-14(8-6-13)19(22)23/h5-8,15,17H,3-4,9-12H2,1-2H3,(H3,22,23)(H,24,27)(H,25,29)/t15-,17+/m1/s1
SMILES Code: O=C(OC)[C@H](CNC(C[C@H]1CC(C2=CC=C(C(N)=N)C=C2)=NO1)=O)NC(OCCCC)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 447.49 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Christen JR, Soubrier C, Martinez E, Roumieu V, Darmon O, Scandaliaris S, Picou L, Cuisset T, Grados A, Bernit E, Ebbo M, Harlé JR, Schleinitz N. [Long-lasting thrombocytopenia induced by glycoprotein IIb/IIIa inhibitor]. Rev Med Interne. 2017 Nov;38(11):769-773. doi: 10.1016/j.revmed.2017.05.013. Epub 2017 Jul 6. French. PubMed PMID: 28690092.
2: Hantgan RR, Stahle MC. Integrin priming dynamics: mechanisms of integrin antagonist-promoted alphaIIbbeta3:PAC-1 molecular recognition. Biochemistry. 2009 Sep 8;48(35):8355-65. doi: 10.1021/bi900475k. PubMed PMID: 19640007.
3: Barrett YC, Ebling W, Pieniaszek H, Billheimer J, Seiffert D. Validation and implementation of drug-dependent antibody assays in clinical trials for safety monitoring of patients dosed with roxifiban, an orally bioavailable glycoprotein IIb/IIIa antagonist. J Pharm Biomed Anal. 2007 Aug 15;44(4):938-46. Epub 2007 Mar 31. PubMed PMID: 17485191.
4: Mousa SA. In-vitro efficacy of different platelet glycoprotein IIb/IIIa antagonists and thrombolytics on platelet/fibrin-mediated clot dynamics in human whole blood using thrombelastography. Blood Coagul Fibrinolysis. 2007 Jan;18(1):55-60. PubMed PMID: 17179828.
5: Hantgan RR, Stahle MC, Connor JH, Connor RF, Mousa SA. AlphaIIbbeta3 priming and clustering by orally active and intravenous integrin antagonists. J Thromb Haemost. 2007 Mar;5(3):542-50. Epub 2006 Dec 13. PubMed PMID: 17166246.
6: Mousa SA, Ahmad S. Platelet GPIIb/IIIa antagonist, XV459, in heparin-induced thrombocytopenia. Am J Hematol. 2007 Apr;82(4):276-82. PubMed PMID: 17039513.
7: Mousa SA, Bozarth JM, Seiffert D, Feuerstein GZ. Using thrombelastography to determine the efficacy of the platelet glycoprotein IIb/IIIa antagonist, roxifiban, on platelet/fibrin-mediated clot dynamics in humans. Blood Coagul Fibrinolysis. 2005 Apr;16(3):165-71. PubMed PMID: 15795533.
8: Murphy J, Wright RS, Gussak I, Williams B, Daly RN, Cain VA, Pieniaszek HJ, Sy SK, Ebling W, Simonson K, Wilcox RA, Kopecky SL. The use of roxifiban (DMP754), a novel oral platelet glycoprotein IIb/IIIa receptor inhibitor, in patients with stable coronary artery disease. Am J Cardiovasc Drugs. 2003;3(2):101-12. PubMed PMID: 14727937.
9: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2003 Nov;25(9):747-71. PubMed PMID: 14685303.
10: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2003 Oct;25(8):653-82. PubMed PMID: 14671684.
11: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2003 Sep;25(7):565-97. PubMed PMID: 14571286.
12: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2003 Jul-Aug;25(6):483-506. PubMed PMID: 12949633.
13: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2003 Jun;25(5):387-408. PubMed PMID: 12851663.
14: Serebruany VL, Malinin AI, O'connor CM, Gurbel PA; Roxifiban Oral Compound Kinetics Evaluation Trial-I Platelet Substudy. Effects of roxifiban on platelet aggregation and major receptor expression in patients with coronary artery disease for the Roxifiban Oral Compound Kinetics Evaluation Trial-I (ROCKET-I Platelet Substudy). Am Heart J. 2003 Jul;146(1):91-8. PubMed PMID: 12851613.
15: Seiffert D, Thomas BE, Bradley JD, Munzer DA, Tchinnes MA, Kornhauser DM, Cain VA, Hua TA, Feuerstein GZ, Martin DE, Stern AM. Effects of the glycoprotein IIb/IIIa antagonist Roxifiban on P-selectin expression, fibrinogen binding, and microaggregate formation in a phase I dose-finding study: no evidence for platelet activation during treatment with a glycoprotein IIb/IIIa antagonist. Platelets. 2003 May;14(3):179-87. PubMed PMID: 12850842.
16: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2003 Apr;25(3):225-48. Review. PubMed PMID: 12743628.
17: Shi G, Lloyd TL, Sy SK, Jiao Q, Wernicki A, Mutlib A, Emm TA, Unger SE, Pieniaszek HJ Jr. Simultaneous quantification of seven active metabolites of roxifiban in human plasma by LC/MS/MS in the presence of an interfering displacer at millimolar concentrations. J Pharm Biomed Anal. 2003 Apr 1;31(5):937-51. PubMed PMID: 12684106.
18: Pedicord DL, Dicker I, O'Neil K, Breth L, Wynn R, Hollis GF, Billheimer JT, Stern AM, Seiffert D. CD32-dependent platelet activation by a drug-dependent antibody to glycoprotein IIb/IIIa antagonists. Thromb Haemost. 2003 Mar;89(3):513-21. PubMed PMID: 12624636.
19: Seiffert D, Pedicord DL, Kieras CJ, He B, Stern AM, Billheimer JT. Regulation of clot retraction by glycoprotein IIb/IIIa antagonists. Thromb Res. 2002 Nov 1;108(2-3):181-9. PubMed PMID: 12590956.
20: Billheimer JT, He B, Spitz SM, Stern AM, Seiffert D. Effects of glycoprotein IIb/IIIa antagonists on platelet activation: development of a transfer method to mimic peak to trough receptor occupancy. Thromb Res. 2002 Sep 15;107(6):303-17. PubMed PMID: 12565717.
